| Budget Amount *help |
¥15,080,000 (Direct Cost: ¥11,600,000、Indirect Cost: ¥3,480,000)
Fiscal Year 2016: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2014: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Outline of Final Research Achievements |
Some cases with multiple sclerosis (MS) are atypical, and they may include unique clinical entities which can be distinguishable from typical MS in terms of the clinical and pathophysiological findings. In the present study, we applied a highly-specific cell-based assay to detect myelin oligodendrocyte glycoprotein (MOG) antibodies and clarified the unique clinical, MRI and pathological features and the therapeutic responses of the myelin antibody-positive cases which can be diagnosed with atypical MS. We also reported “MOG-antibody-positive, unilateral cerebral cortical encephalitis with epilepsy”, a new type of autoimmune encephalitis. Moreover, we found that the interplay between the tissue preconditioning to hypoxic stimuli and glial cell-derived cytokines associated with demyelination appears to contribute to the unique pathology of Balo’s concentric sclerosis.
|
